Corning Incorporated and Geron Corporation Showcase New Synthetic Surface Matrices to Enhance Stem Cell Growth
21 Settembre 2009 - 2:30PM
Business Wire
Corning Incorporated (NYSE: GLW) and Geron Corporation (Nasdaq:
GERN) today announced the successful development of novel synthetic
surface matrices demonstrated to enhance and support the scalable
manufacturing and growth of human embryonic stem cells (hESCs).
Through its ongoing collaboration with Geron, Corning has
developed a synthetic surface that supports the growth and
differentiation of hESCs in a defined (animal-free) medium. Data
presented today at the World Stem Cell Summit in Baltimore, Md.,
will show multi-passage growth of multiple undifferentiated hESC
lines and the subsequent differentiation of one of these cell lines
into cardiomyocytes. The growth and differentiation of hESCs on
this surface is robust and reproducible, an important condition for
the large-scale production of cells and therapeutic development.
Data will specifically be presented in a poster titled, “Synthetic
Peptide-Acrylate Surfaces for Long-Term Self-Renewal and
Cardiomyocyte Differentiation of Human Embryonic Stem Cells in
Defined Medium.”
“We are excited to share the results our research with Geron has
generated with the scientific community,” said Dr. Jeff Mooney,
director of commercial technology for Corning Life Sciences. “This
collaboration is an example of our commitment to bringing Corning’s
unique expertise in materials and surfaces to enhance cell growth
and deliver critical products to the life sciences industry.”
Since 2006, Corning has worked with Geron to develop synthetic
surface matrices to support the scalable manufacturing of hESCs and
differentiated cell types derived from them. Synthetic growth
surfaces could replace the biological surface coatings that are
widely used today to grow and differentiate pluripotent stem cells
and may offer increased reproducibility, cost savings, and
regulatory advantages.
“We are pleased with the achievements to date of our
collaborative efforts with Corning,” said Dr. Jane S. Lebkowski,
Geron’s senior vice president and chief scientific officer for
regenerative medicine. “Together our teams have developed a
synthetic surface that can be manufactured into multiple culture
vessel formats and directly supports the growth and differentiation
of hESCs. Geron scientists have previously established techniques
for feeder-free growth of hESCs and this is the important next step
for scalable and cost-effective manufacturing of therapies for
degenerative diseases from hESCs.”
Laboratory products using specialized surfaces resulting from
this collaboration will be commercialized by Corning subject to
certain commercial use restrictions. Geron will receive a royalty
on future product sales and has exclusive rights to use the
surfaces in the manufacturing of certain therapeutic products.
Through this collaboration, a platform of surfaces is in
development to support the needs of stem cell researchers worldwide
in their efforts to grow specific cells in quantities desired for
research purposes.
Corning Life Sciences brings new and innovative laboratory
technologies to researchers worldwide and helps customers succeed
by providing innovative, high-quality products and services in the
areas of polymer science, biochemistry and molecular biology, glass
melting and forming, surface modification, and characterization
science.
About Corning Incorporated
Corning Incorporated (www.corning.com) is the world leader in
specialty glass and ceramics. Drawing on more than 150 years of
materials science and process engineering knowledge, Corning
creates and makes keystone components that enable high-technology
systems for consumer electronics, mobile emissions control,
telecommunications and life sciences. Our products include glass
substrates for LCD televisions, computer monitors and laptops;
ceramic substrates and filters for mobile emission control systems;
optical fiber, cable, hardware & equipment for
telecommunications networks; optical biosensors for drug discovery;
and other advanced optics and specialty glass solutions for a
number of industries including semiconductor, aerospace, defense,
astronomy and metrology.
About Geron Corporation
Geron is developing first-in-class biopharmaceuticals for the
treatment of cancer and chronic degenerative diseases, including
spinal cord injury, heart failure and diabetes. The company is
advancing an anti-cancer drug and a cancer vaccine that target the
enzyme telomerase through multiple clinical trials in different
cancers. For more information, visit www.geron.com.
Corning Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” (within
the meaning of the Private Securities Litigation Reform Act of
1995), which are based on current expectations and assumptions
about Corning’s financial results and business operations, that
involve substantial risks and uncertainties that could cause actual
results to differ materially. These risks and uncertainties
include: the effect of global political, economic and business
conditions; conditions in the financial and credit markets;
currency fluctuations; tax rates; product demand and industry
capacity; competition; reliance on a concentrated customer base;
manufacturing efficiencies; cost reductions; availability of
critical components and materials; new product commercialization;
pricing fluctuations and changes in the mix of sales between
premium and non-premium products; new plant start-up or
restructuring costs; possible disruption in commercial activities
due to terrorist activity, armed conflict, political instability or
major health concerns; adequacy of insurance; equity company
activities; acquisition and divestiture activities; the level of
excess or obsolete inventory; the rate of technology change; the
ability to enforce patents; product and components performance
issues; stock price fluctuations; and adverse litigation or
regulatory developments. These and other risk factors are detailed
in Corning’s filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the day that they are
made, and Corning undertakes no obligation to update them in light
of new information or future events.
Geron Safe Harbor
This news release may contain forward-looking statements made
pursuant to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that
statements in this press release regarding potential applications
of Geron’s human embryonic stem cell technology constitute
forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development
and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need
for future capital, dependence upon collaborators and maintenance
of Geron’s intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect Geron’s results and other risks and uncertainties are
detailed from time to time in Geron’s periodic reports, including
the quarterly report on Form 10-Q for the quarter ended June 30,
2009.
Grafico Azioni Corning (NYSE:GLW)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Corning (NYSE:GLW)
Storico
Da Ott 2023 a Ott 2024